- SEK1.36bn
- SEK1.05bn
Brief: Index Pharmaceuticals Gets Patent For Cobitolimod in US
Brief: InDex Pharmaceuticals Q2 Operating Loss Widens To SEK 42.6 Mln
Brief: Index Pharmaceuticals Receives FDA Clearance To Start The Phase III Study Conclude With Cobitolimod
Brief: Index Pharmaceuticals Receives First Regulatory Approval To Start The Phase III Study Conclude With cobitolimod
Brief: Index Pharmaceuticals Says Will Initiate Patient Recruitment For The Phase III Study CONCLUDE After The Summer
Life science investor Linc AB plans Stockholm IPO (updated)
Brief: InDex Pharmaceuticals Q1 Operating Loss Narrows To SEK 9.3 Mln
Brief: Index Pharmaceuticals Gets Patent For Additional DIMS Compounds Granted In Europe
Brief: Index Pharmaceuticals Enters Agreement With Parexel Biotech
Brief: Index Pharmaceuticals Holding AB - Q4 Result After Tax Amounted To Sek -10.1 Million
Brief: InDex Pharmaceuticals' Rights Issue Is Oversubscribed
Brief: InDex Pharmaceuticals Carries Out Fully Guaranteed Rights Issue Of Around SEK 533 Mln
Brief: Index Pharmaceuticals Q3 Operating Loss Narrows To SEK 7.7 Mln
Brief: InDex Pharmaceuticals To Carry Out Rights Issue Of About SEK 500 Mln
Brief: Index Pharmaceuticals Q2 Operating Loss At SEK 15.6 Mln
Brief: Index Pharmaceuticals To Present Successful Results Of Conduct Study
Brief: Index Pharmaceuticals Q1 Operating Loss Widens To SEK 24.0 Mln
Brief: Index Pharmaceuticals Advances Cobitolimod Further Towards Phase III
Brief: Index Pharmaceuticals Gets Grant From Vinnova